Although no significant effect of CYP3A4, CYP2C19 and CYP2C9 genotypes was observed on schistosomiasis treatment efficacy and adverse events, the borderline association of CYP3A5 genotype with treatment-associated adverse events requires further investigation. Here, CYP2C19 is linked to schistosomiasis.